Dysresgulated metabolic pathways contribute to several diseases, including cancer. The discovery and functional characterization of biochemical pathways that support cancer have, however, been hindered by a lack of technologies that can broadly profile metabolites, enzymes, and metabolite- protein interactions in native biological systems. We have addressed this central problem through the development and application of an innovative set of chemical proteomic and metabolomic technologies. In this competitive renewal application, we propose to use and expand our chemical proteomic and metabolomic methods towards the two major goals of: 1) characterizing metabolic (de)methylation pathways that support the growth and malignant properties of cancer cells, and 2) globally mapping and characterizing metabolite-protein interactions that support the growth and malignant properties of cancer cells. These studies are designed to test three major hypotheses: 1) dysregulated metabolic enzymes coordinately control the methylation potential, epigenetic state, and pro-tumorigenic properties of cancer cells, 2) photoreactive, clickable probes offer a general chemoproteomic strategy to map metabolite-protein interactions in living cells, and 3) mapping the full complement of proteins that bind to bioactive sterols and lipids in tumor cells will uncover new biochemical nodes of regulation and crosstalk that define metabolic dependencies of cancers. The ultimate goal of this application is to identify and functionally characterize metabolic pathways that are dysregulated in cancer and support tumorigenesis. The molecular components of these pathways may, in turn, represent new biomarkers and drug targets for the diagnosis and treatment of cancer. The research tools and methods advanced in this proposal should also prove of general value for characterizing biochemical networks in a wide range of physiological and disease processes.
Cancer cells depend on specialized metabolic and signaling pathways for viability and malignancy. The goal of this application is to develop and apply innovative technologies to discover metabolic pathways that are dysregulated in cancer cells and support tumorigenesis. The components of these pathways could in turn serve as new biomarkers and therapeutic targets for the diagnosis and treatment of cancer.
|Kambe, Tohru; Correia, Bruno E; Niphakis, Micah J et al. (2014) Mapping the protein interaction landscape for fully functionalized small-molecule probes in human cells. J Am Chem Soc 136:10777-82|
|Niphakis, Micah J; Cravatt, Benjamin F (2014) Enzyme inhibitor discovery by activity-based protein profiling. Annu Rev Biochem 83:341-77|
|Simon, Gabriel M; Niphakis, Micah J; Cravatt, Benjamin F (2013) Determining target engagement in living systems. Nat Chem Biol 9:200-5|
|Hulce, Jonathan J; Cognetta, Armand B; Niphakis, Micah J et al. (2013) Proteome-wide mapping of cholesterol-interacting proteins in mammalian cells. Nat Methods 10:259-64|
|Ulanovskaya, Olesya A; Zuhl, Andrea M; Cravatt, Benjamin F (2013) NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol 9:300-6|
|Zuhl, Andrea M; Mohr, Justin T; Bachovchin, Daniel A et al. (2012) Competitive activity-based protein profiling identifies aza-?-lactams as a versatile chemotype for serine hydrolase inhibition. J Am Chem Soc 134:5068-71|
|Bachovchin, Daniel A; Cravatt, Benjamin F (2012) The pharmacological landscape and therapeutic potential of serine hydrolases. Nat Rev Drug Discov 11:52-68|
|Moellering, Raymond E; Cravatt, Benjamin F (2012) How chemoproteomics can enable drug discovery and development. Chem Biol 19:11-22|
|Long, Jonathan Z; Cravatt, Benjamin F (2011) The metabolic serine hydrolases and their functions in mammalian physiology and disease. Chem Rev 111:6022-63|
|Bachovchin, Daniel A; Mohr, Justin T; Speers, Anna E et al. (2011) Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors. Proc Natl Acad Sci U S A 108:6811-6|
Showing the most recent 10 out of 21 publications